Sunshine Biopharma Inc. Quarterly Common Stock, Shares, Issued from Q4 2010 to Q4 2024

Taxonomy & unit
us-gaap: shares
Description
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Summary
Sunshine Biopharma Inc. quarterly Common Stock, Shares, Issued history and growth rate from Q4 2010 to Q4 2024.
  • Sunshine Biopharma Inc. Common Stock, Shares, Issued for the quarter ending December 31, 2024 was 2.58M shares.
Common Stock, Shares, Issued, Quarterly (shares)
Common Stock, Shares, Issued, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 2.58M +2.57M Dec 31, 2024 10-K 2025-04-01
Q3 2024 2M -23.7M -92.2% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 1.17M -24.6M -95.5% Jun 30, 2024 10-Q/A 2024-08-20
Q1 2024 995K -21.1M -95.5% Mar 31, 2024 10-Q 2024-05-20
Q4 2023 14K* -22.6M Dec 31, 2023 10-K 2025-04-01
Q3 2023 25.7M +6.79M +36% Sep 30, 2023 10-Q 2023-11-13
Q2 2023 25.7M +6.86M +36.3% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 22.1M +15M +210% Mar 31, 2023 10-Q 2023-05-10
Q4 2022 22.6M +20M +772% Dec 31, 2022 10-K 2024-03-28
Q3 2022 18.9M -491M -96.3% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 18.9M -467M -96.1% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 7.15M -458M -98.5% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 2.59M +859K +49.6% Dec 31, 2021 10-K 2023-04-04
Q3 2021 510M +206M +67.6% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 486M +216M +80.2% Jun 30, 2021 10-Q 2021-08-09
Q1 2021 465M +405M +679% Mar 31, 2021 10-Q 2021-05-11
Q4 2020 1.73M -33.6M -95.1% Dec 31, 2020 10-K 2022-03-21
Q3 2020 304M -7.01M -2.25% Sep 30, 2020 10-Q 2020-11-12
Q2 2020 270M +166M +159% Jun 30, 2020 10-Q/A 2020-08-31
Q1 2020 59.7M -29.7M -33.2% Mar 31, 2020 10-Q 2020-05-18
Q4 2019 35.3M +31M +725% Dec 31, 2019 10-K 2021-03-30
Q3 2019 311M -1.27B -80.4% Sep 30, 2019 10-Q 2019-11-13
Q2 2019 104M -1B -90.6% Jun 30, 2019 10-Q 2019-08-15
Q1 2019 89.3M -860M -90.6% Mar 31, 2019 10-Q 2019-05-20
Q4 2018 4.28M -41.7M -90.7% Dec 31, 2018 10-K 2020-05-01
Q3 2018 1.59B +667M +72.6% Sep 30, 2018 10-Q 2018-11-16
Q2 2018 1.1B +236M +27.1% Jun 30, 2018 10-Q 2018-08-17
Q1 2018 949M +131M +16% Mar 31, 2018 10-Q 2018-05-22
Q4 2017 45.9M -723M -94% Dec 31, 2017 10-K 2019-04-12
Q3 2017 919M +283M +44.5% Sep 30, 2017 10-Q 2017-11-15
Q2 2017 869M +594M +217% Jun 30, 2017 10-Q 2017-08-11
Q1 2017 818M +585M +251% Mar 31, 2017 10-Q 2017-05-12
Q4 2016 769M +571M +288% Dec 31, 2016 10-K 2018-04-02
Q3 2016 636M +502M +373% Sep 30, 2016 10-Q 2016-11-14
Q2 2016 274M +148M +117% Jun 30, 2016 10-Q 2016-08-16
Q1 2016 233M +130M +127% Mar 31, 2016 10-Q 2016-05-09
Q4 2015 198M +125M +170% Dec 31, 2015 10-K 2017-04-17
Q3 2015 134M +65.5M +95% Sep 30, 2015 10-Q 2015-11-04
Q2 2015 126M +60.5M +91.7% Jun 30, 2015 10-Q 2015-08-06
Q1 2015 102M +39.8M +63.5% Mar 31, 2015 10-Q 2015-05-07
Q4 2014 73.6M +13.3M +22% Dec 31, 2014 10-K 2016-03-25
Q3 2014 68.9M +12.1M +21.2% Sep 30, 2014 10-Q 2014-11-12
Q2 2014 66M +9.53M +16.9% Jun 30, 2014 10-Q 2014-08-12
Q1 2014 62.7M +6.49M +11.5% Mar 31, 2014 10-Q 2014-05-09
Q4 2013 60.3M +8.88M +17.3% Dec 31, 2013 10-K 2015-03-11
Q3 2013 56.8M +5.45M +10.6% Sep 30, 2013 10-Q 2013-11-04
Q2 2013 56.4M +7.23M +14.7% Jun 30, 2013 10-Q 2013-08-06
Q1 2013 56.2M +7.46M +15.3% Mar 31, 2013 10-Q 2013-05-09
Q4 2012 51.4M +2.69M +5.52% Dec 31, 2012 10-K 2014-03-19
Q3 2012 51.4M +20.4M +65.6% Sep 30, 2012 10-Q 2012-11-08
Q2 2012 49.2M +18.5M +60.2% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 48.7M +18M +58.7% Mar 31, 2012 10-Q 2012-05-08
Q4 2011 48.7M +18M +58.8% Dec 31, 2011 10-K 2013-03-15
Q3 2011 31M Sep 30, 2011 10-Q 2011-11-08
Q2 2011 30.7M Jun 30, 2011 10-Q 2011-08-09
Q1 2011 30.7M Mar 31, 2011 10-Q 2011-05-12
Q4 2010 30.7M Dec 31, 2010 10-K 2012-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.